1.
Fanning S, Haque A, Imberdis T, et al. Lipidomic Analysis of α-Synuclein Neurotoxicity Identifies Stearoyl CoA Desaturase as a Target for Parkinson Treatment. Mol Cell. 2019;73(5):1001-1014.e8. doi:10.1016/j.molcel.2018.11.028.
1.
Kamath T, Abdulraouf A, Burris SJ, et al. Single-cell genomic profiling of human dopamine neurons identifies a population that selectively degenerates in Parkinson’s disease. Nat Neurosci. 2022;25(5):588-595. doi:10.1038/s41593-022-01061-1.
1.
Heyer MP, Pani AK, Smeyne RJ, Kenny PJ, Feng G. Normal midbrain dopaminergic neuron development and function in miR-133b mutant mice. J Neurosci. 2012;32(32):10887-94. doi:10.1523/JNEUROSCI.1732-12.2012.
1.
Fieblinger T, Graves SM, Sebel LE, et al. Cell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia. Nat Commun. 2014;5:5316. doi:10.1038/ncomms6316.
1.
Woodard CM, Campos BA, Kuo S-H, et al. iPSC-derived dopamine neurons reveal differences between monozygotic twins discordant for Parkinson’s disease. Cell Rep. 2014;9(4):1173-82. doi:10.1016/j.celrep.2014.10.023.
1.
Zhao B, Zhu J, Dai D, et al. Differential dopaminergic regulation of inwardly rectifying potassium channel mediated subthreshold dynamics in striatal medium spiny neurons. Neuropharmacology. 2016;107:396-410. doi:10.1016/j.neuropharm.2016.03.037.